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Background: Optimal aspirin (ASA) dosing post-ACS remains uncertain; PLATO showed regional variation of ASA dosing and decreased benefit 
of ticagrelor with high dose ASA. TRITON-TIMI 38 provided a unique opportunity to assess predictors of ASA dosing post-ACS and relationship to CV 
events.
Methods: We analyzed 11,716 patients (pts) in TRITON who survived to discharge free of MI, stroke, stent thrombosis, bleed or CABG; pts missing 
ASA dose were excluded. Pts were divided as per ASA discharge dose into low-dose (<150 mg) or high-dose (≥150 mg). Adjusted HRs were derived 
for post-discharge events stratified by ASA dose. Interaction between study therapy, prasugrel (pras) vs. clopidogrel (clop), and ASA dose was 
assessed.
Results: High dose ASA was given to 66% of pts in N. America, 37% in S. America, 30% in W. Europe, 24% in E. Europe and 27% in the rest of world. 
Additional independent correlates of higher ASA dose were age <75y, prior MI, timing of PCI load, antithrombin type, lack of GP2b/3a inhibitor use. 
The favorable effect of pras on CV death/MI/stroke was unchanged by ASA dose group (pinteraction=0.80). The increased TIMI major non-CABG 
bleeding in pts randomized to pras vs. clop was also independent of ASA dose group (pinteraction=0.52) (Figure).
Conclusion: In TRITON-TIMI 38, we report correlates of ASA dose and confirmed greater use of high dose ASA at discharge in N. America. The effects 
of prasugrel on safety and efficacy were similar regardless of aspirin dose in pts who were event free at the time of discharge.
 
